• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1266243 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
6 C' B0 @- K: Y/ P$ J% K+ T- uNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 % x- N% Z9 a1 f# q' T0 K
+ Author Affiliations, A4 g0 x+ b0 `# L

( h( s8 R- Q( F3 `' d1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
1 ?, @; z7 w0 l  A# m  r2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
+ J) R$ h* H$ o3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
0 U, D9 U) \5 T# X6 y+ o4 u4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
5 z- ~8 `; H4 R; ~, u5 d0 f( \) g5 ~5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan   \7 h/ n5 z( S% I
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
1 l9 H/ {% y, Y- b9 R+ z7Kinki University School of Medicine, Osaka 589-8511, Japan % p, A4 Q: W' C! ]/ A
8Izumi Municipal Hospital, Osaka 594-0071, Japan
9 r) W% |2 i+ |; d" i/ |9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
6 [0 I3 S; y# k7 v+ X6 r: fCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp 2 k7 G3 H% h; r
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
+ P6 g, W9 o/ ]+ f; g' l* F* |& N- P
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type - g# [3 E( t9 H/ \4 m% J

1 t. w2 z2 S+ C* e' r, QAuthors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato 4 I4 A- u3 `; o' h0 u/ K+ l2 Z
- \# N7 e: A; z" ~& b
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  2 `$ P8 Q4 K: w1 y# d6 L
2 I2 w* S* c) c1 s, F. w6 C
Published online on: Thursday, December 1, 2011 3 S# A2 ?  |( T7 g! N  O2 c& j6 U; y
! A3 B' z$ P8 p$ p+ B7 T; N
Doi: 10.3892/ol.2011.507
. |/ l% u3 [' u* ^+ _  i7 T, q2 {
Pages: 405-410 0 }2 y( ?3 C8 w& q! A* u9 S; U

$ I' j0 l* D% y% e7 H' LAbstract:0 y. }1 C) @  G/ R) _3 Q6 r
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.  O' N! F: e  G9 {9 F. y. t# |: ^9 h. T

5 W% j; G: ?* d2 b- U
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
! V2 h4 |: Y5 o9 z- J) q4 K( vF. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 * f( i5 F- }0 b0 H( y
+ Author Affiliations* d+ h; V1 @3 N6 @% \7 i
1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu . q2 K- s# N! R0 r. ]2 g
2Department of Thoracic Surgery, Kyoto University, Kyoto
7 W6 _' e$ @, P' v! b# Z9 d3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
" K) B. Q3 H" Q* d' D' P6 c&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
, W/ y) p' S( a! b: N5 RReceived September 3, 2010.
1 b2 V7 F, m% ]Revision received November 11, 2010. # c6 {4 `. A# Z. `: g
Accepted November 17, 2010.
4 I, S! f, f2 c. Q" z9 aAbstract9 m$ O& s0 F4 b. P3 ]9 y
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
5 I+ ?' z9 f; ?# b) W) t% @1 uPatients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
& U% l+ `- @( ]+ d* ~; zResults: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
( o# |, C: s8 d' c/ h0 S6 }6 v0 EConclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.
/ v( @+ R8 l4 p4 ^
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。7 Z1 R1 j4 L3 a' x( @. X
今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?
; s3 x( ?, x# {; s
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy. c& f/ \7 \0 J
http://clinicaltrials.gov/ct2/show/NCT01523587
3 i* c7 {) x. [" ~5 c0 z* Y& W! \
7 D( e  g+ g6 u0 xBIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
- B1 ^0 P# C  D3 g7 b% I6 thttp://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 " W( k' V* |, P8 {0 Q
6 K% V+ Q" g7 I" q
从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。# g9 L$ }/ I' u8 v  ?7 }8 D
至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
5 {' W, |* e- L; d3 t8 |
没有副作用是第一追求,效果显著是第二追求。: ]# D6 y9 z, c+ G  Q7 h+ m# J
不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表